CAS 1339928-25-4
:CUDC-907
Description:
CUDC-907 is a small molecule inhibitor that targets both histone deacetylases (HDACs) and phosphatidylinositol 3-kinase (PI3K) pathways, making it a dual-action therapeutic agent. It is primarily investigated for its potential in treating various cancers, particularly those with aberrant signaling through these pathways. The compound exhibits a unique mechanism of action by modulating gene expression and promoting apoptosis in cancer cells. CUDC-907 has shown promise in preclinical studies, demonstrating efficacy in inhibiting tumor growth and overcoming resistance to other therapies. Its chemical structure includes functional groups that facilitate its interaction with target enzymes, enhancing its potency and selectivity. Additionally, the pharmacokinetic profile of CUDC-907 is designed to optimize bioavailability and minimize off-target effects, which is crucial for its therapeutic application. Ongoing research aims to further elucidate its safety, efficacy, and potential combination strategies with other anticancer agents in clinical settings.
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 6 products.
N-Hydroxy-2-(((2-(6-Methoxypyridin-3-Yl)-4-Morpholinothieno[3,2-D]Pyrimidin-6-Yl)Methyl)(Methyl)Amino)Pyrimidine-5-Carboxamide
CAS:N-Hydroxy-2-(((2-(6-Methoxypyridin-3-Yl)-4-Morpholinothieno[3,2-D]Pyrimidin-6-Yl)Methyl)(Methyl)Amino)Pyrimidine-5-CarboxamideFormula:C23H24N8O4SPurity:98%Molecular weight:508.55Fimepinostat
CAS:Fimepinostat (CUDC 907) is an orally bioavailable inhibitor of both PI3K class I and pan-HDAC enzymes, with potential antineoplastic activity.Formula:C23H24N8O4SPurity:98.27% - 99.87%Color and Shape:SolidMolecular weight:508.55Ref: TM-T2078
2mg44.00€5mg66.00€1mL*10mM (DMSO)74.00€10mg92.00€25mg172.00€50mg295.00€100mg485.00€500mg1,035.00€Fimepinostat
CAS:N-Hydroxy-2-(((2-(6-methoxypyridin-3-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)(methyl)amino)pyrimidine-5-carboxamideFormula:C23H24N8O4SPurity:98%Molecular weight:508.55
